Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MGMT | P16455 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795544 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TDP1SMN1; SMN2MAPTNPY1R | |
| SCHEMBL240574 | 0.84 | TDP1 (0.52) | ALDH1A1TDP1SMN1; SMN2MAPTMGMT | |
| SCHEMBL3390153 | 0.84 | TDP1 (0.52) | ALDH1A1TDP1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL11551067 | 0.84 | TDP1 (0.52) | ALDH1A1TDP1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL15861931 | 0.83 | SMN1; SMN2 (0.40) | ALDH1A1TDP1SMN1; SMN2MAPTNPY1R | |
| SCHEMBL11901676 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TDP1SMN1; SMN2MAPTNPY1R | |
| Hydrochloric Acid SCHEMBL5914596 | 0.82 | TDP1 (0.50) | ALDH1A1TDP1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL8066551 | 0.81 | MEN1 (0.44) | ALDH1A1TDP1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2843518 | 0.77 | TDP1 (0.45) | ALDH1A1TDP1SMN1; SMN2MAPTNPY1R | |
| SCHEMBL17934 | 0.77 | TSHR (0.59) | ALDH1A1TDP1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100456398-C | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORP (JP) | 2009-01-28 | — | — | CN | claimed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | claimed |
| EP-0743848-B1 | 2-FLUORO-6-NITROANILINES | HENKEL KGAA (DE) | 2000-11-08 | — | — | EP | claimed |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIV DE MONTREAL (CA) | 2026-05-21 | — | — | US | disclosed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4665456-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | Arvinas Operations, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| CN-100477037-C | Electrolytic capacitor and electrolyte for driving electrolytic capacitor | RUBYCON CORP (JP) | 2009-04-08 | — | — | CN | disclosed |
| CN-100456398-C | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORP (JP) | 2009-01-28 | — | — | CN | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | disclosed |
| CN-1494723-A | Electrolytic capacitor and electrolyte for driving electrolytic capacitor | 如碧空株式会社 | 2004-05-05 | — | — | CN | disclosed |
| CN-1333770-A | Novel Bicyclic Compounds | BASLIER PHARMACEUTICAL AG (CH) | 2002-01-30 | — | — | CN | disclosed |
| US-RE30798-E | BY REACTING 4-FLUORO-3-NITROANILINES WITH AMMONIA OR A PRIMARY OR SECONDARY AMINE | CLAIROL INCORPORATED (US) | 1981-11-17 | — | — | US | disclosed |
| US-3944612-A | HAIR DYE INTERMEDIATES | CLAIROL INCORPORATED (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | SGK1, PBK, SGK3 | ALDH1A1 4640/4885TDP1 2979/4885SMN1; SMN2 4675/4885 |
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ALDH1A1 4159/4885TDP1 963/4885SMN1; SMN2 2602/4885 |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, KRAS, BRAF | ALDH1A1 2369/4885TDP1 1807/4885SMN1; SMN2 3532/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | ALDH1A1 3225/4885TDP1 3310/4885SMN1; SMN2 89/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | ALDH1A1 1619/4885TDP1 489/4885SMN1; SMN2 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.